Medexus Pharmaceuticals Reports Operating and Financial Results for the First Quarter of Fiscal 2020
August 22, 2019 16:01 ET
|
Medexus Pharmaceuticals Inc
Record Revenue of $16.1 Million $0.5 million of Adjusted EBITDA Medexus management to host conference call at 4:30 PM ET on Thursday, August 22, 2019 TORONTO and CHICAGO and MONTREAL, Aug. 22,...
Medexus Pharmaceuticals Schedules First Quarter Fiscal 2020 Conference Call
August 16, 2019 11:00 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM...
Medexus Announces DTC Eligibility of its Common Shares in the United States
August 15, 2019 16:05 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that the Company's common shares traded in the...
Medexus Pharmaceuticals Announces Operating and Financial Results for Fourth Quarter and Full Fiscal Year Ended March 31, 2019
July 08, 2019 16:05 ET
|
Medexus Pharmaceuticals Inc
Generated $2.4 million of Adjusted EBITDA for fiscal year 2019 Medexus management to host conference call at 4:30 PM ET on July 8, 2019 MONTREAL, July 08, 2019 (GLOBE NEWSWIRE) -- Medexus...
Medexus Pharmaceuticals Schedules Fourth Quarter and Fiscal 2019 Conference Call
June 28, 2019 08:00 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, June 28, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM...
Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors
June 25, 2019 08:00 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, June 25, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North...
Medexus Pharmaceuticals Announces Normal Course Issuer Bid
May 14, 2019 08:00 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, Quebec, May 14, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”) (TSXV: MDP, OTCQB: PDDPF) announced today it has submitted to the TSX Venture Exchange (the...
Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis in Canada
May 07, 2019 12:43 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose...
Medexus CEO to Present at Two Upcoming Investor Conferences
April 23, 2019 08:00 ET
|
Medexus Pharmaceuticals Inc
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces that Ken d’Entremont, Chief Executive Officer, has been...
Santé Canada autorise Medexus à distribuer tréosulfan au Canada
March 07, 2019 13:30 ET
|
Medexus Pharmaceuticals Inc
Début des envois aux hôpitaux dans le cadre du Programme d’accès spécial Des plans sont en cours pour demander un enregistrement complet au Canada MONTRÉAL, 07 mars 2019 (GLOBE NEWSWIRE)...